Related Experiment Video
Updated: Jan 14, 2026

Phage-Mediated Genetic Manipulation of the Lyme Disease Spirochete Borrelia burgdorferi
Published on: September 28, 2022
Phage vB_KpnM_JYSS3 encodes a novel polysaccharide depolymerase that exhibits specific activity against K2-type
Shi-Yan Jiao1, Xia Wang1, Jie Wang1
1College of Lab Medicine, Hebei North University, Zhangjiakou, Hebei Province, 075000, People's Republic of China.
Background:
Carbapenem-resistant Klebsiella pneumoniae (CRKP), a major nosocomial pathogen, poses an increasingly serious threat to human health.
Results:
In the quest for innovative therapeutic modalities to treat CRKP infections, a newly discovered phage, vB_KpnM_JYSS3, which can specifically infect and lyse K2-type CRKP, was isolated and subjected to an array of comprehensive characterizations and genome sequencing. Furthermore, an analysis of the expression of the tail protein (ORF17) and the detection of its functions were carried out. Double-layer agar plates containing CRKP were used to isolate phages from hospital sewage samples. The phage's optimal multiplicity of infection (MOI), lytic spectrum, bactericidal activity, stability, and one-step growth curve were tested. The biofilm development ability of the CRKP strain 21AA2216 and the phage antibiofilm activity were determined using a 96-well microtitration plate. vB_KpnM_JYSS3 prevented biofilm generation and broke down mature biofilms. The whole-genome sequencing results revealed that vB_KpnM_JYSS3 is a toxic phage (nontemperate). The genome size of vB_KpnM_JYSS3 is 47,244 bp, and the G + C content is 48.48 mol%. A total of 71 coding sequences (CDSs) were predicted. Protein function prediction revealed that the tail protein (ORF17) of vB_KpnM_JYSS3 may possess depolymerase activity, consistent with the halo phenomenon around the plaque. ORF17 was expressed, purified, and named Dep17. Dep17 can degrade the capsular polysaccharide (CPS) surrounding K2-type CRKP, and it can also enhance the activity of polymyxin B against K2-type CRKP biofilms.
Conclusions:
Phage vB_KpnM_JYSS3 and its novel depolymerase Dep17 may represent promising strategies for combating infections resulting from biofilm-forming and drug-resistant K2-type CRKP.
Insights
A newly discovered phage, vB_KpnM_JYSS3, effectively targets and lyses carbapenem-resistant Klebsiella pneumoniae (CRKP). Its tail protein, Dep17, degrades bacterial capsules and enhances antibiotic efficacy against CRKP biofilms.
Area of Science:
- Microbiology
- Bacteriology
- Virology
Background:
- Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a significant nosocomial pathogen causing severe infections.
- The rise of CRKP necessitates novel therapeutic strategies due to increasing antimicrobial resistance.
Purpose of the Study:
- To isolate and characterize a novel bacteriophage targeting K2-type CRKP.
- To investigate the antibiofilm activity of the phage and its potential therapeutic applications.
- To identify and analyze specific phage proteins involved in CRKP lysis and biofilm disruption.
Main Methods:
- Isolation of bacteriophages from hospital sewage using double-layer agar plates with CRKP.
- Comprehensive characterization of the isolated phage vB_KpnM_JYSS3, including optimal multiplicity of infection, lytic spectrum, stability, and growth kinetics.
- Genome sequencing of the phage and prediction of coding sequences.
- Expression, purification, and functional analysis of the phage tail protein (ORF17), named Dep17.
- Assessment of antibiofilm activity using 96-well microtitration plates and determination of Dep17's effect on capsular polysaccharide (CPS).
Main Results:
- Isolation and identification of a novel lytic phage, vB_KpnM_JYSS3, specific for K2-type CRKP.
- Phage vB_KpnM_JYSS3 demonstrated significant antibiofilm activity, preventing biofilm formation and degrading mature biofilms.
- Genome sequencing revealed vB_KpnM_JYSS3 as a nontemperate phage with a genome size of 47,244 bp, containing 71 predicted coding sequences.
- The tail protein, Dep17, was confirmed to possess depolymerase activity, degrading the CPS of K2-type CRKP.
- Dep17 enhanced the efficacy of polymyxin B against CRKP biofilms.
Conclusions:
- Phage vB_KpnM_JYSS3 represents a promising lytic agent against K2-type CRKP.
- The novel depolymerase, Dep17, shows potential for disrupting CRKP biofilms and enhancing antibiotic treatment.
- Combined phage and depolymerase therapy could offer a novel strategy for combating drug-resistant CRKP infections.
Related Concept Videos
DNA Bacteriophages
Lysogenic Cycle of Bacteriophages
Peptidoglycan Synthesis
Viral Replication: Lytic Cycle
Lytic Cycle of Bacteriophages

